Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults

References

• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97(9):1236–1256. doi: 10.1002/ajh.26642
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Maru Y. Molecular biology of chronic myeloid leukemia. Cancer Sci. 2012;103(9):1601–1610. doi: 10.1111/j.1349-7006.2012.02346.x
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi: 10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Vener C, Banzi R, Ambrogi F, et al. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020;4(12):2723–2735. doi: 10.1182/bloodadvances.2019001329
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi: 10.1038/s41375-020-0776-2
   PubMed Web of Science ®Google Scholar
• Breccia M, Efficace F, Scalzulli E, et al. Measuring prognosis in chronic myeloid leukemia: what’s new? Expert Rev Hematol. 2021;14(6):577–585. doi: 10.1080/17474086.2021.1938534
   PubMed Web of Science ®Google Scholar
• United nations world population prospects 2019. 2020.
   Google Scholar
• Jin Z, Griffith MA, Rosenthal AC. Identifying and meeting the needs of adolescents and young adults with cancer. Curr Oncol Rep. 2021;23(2):17. doi: 10.1007/s11912-020-01011-9
   PubMed Web of Science ®Google Scholar
• Barr RD, Ferrari A, Ries L, et al. Cancer in adolescents and young adults: a narrative review of the current status and a view of the future. JAMA Pediatr. 2016;170(5):495–501. doi: 10.1001/jamapediatrics.2015.4689
   PubMed Web of Science ®Google Scholar
• Coccia PF, Pappo AS, Beaupin L, et al. Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology. J National Compr Cancer Network. 2018;16(1):66–97.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA. Cancer J Clinicians. 2022;72(1):7–33. doi: 10.3322/caac.21708
   Web of Science ®Google Scholar
• Smith AW, Seibel NL, Lewis DR, et al. Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Cancer. 2016;122(7):988–999.
   PubMed Web of Science ®Google Scholar
• Scalzulli E, Colafigli G, Pepe S, et al. Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. Leuk Lymphoma. 2021;62(4):1026–1027. doi: 10.1080/10428194.2020.1808205
   PubMed Web of Science ®Google Scholar
• Aben KK, van Gaal C, van Gils NA, et al. Cancer in adolescents and young adults (15–29 years): A population-based study in the Netherlands 1989–2009. Acta Oncol. 2012;51(7):922–933. doi: 10.3109/0284186X.2012.705891
   PubMed Web of Science ®Google Scholar
• Pollock BH, Birch JM. Registration and classification of adolescent and young adult cancer cases. Pediatr Blood Cancer. 2008;50(5 Suppl):1090–1093. doi: 10.1002/pbc.21462
   PubMed Web of Science ®Google Scholar
• Nishiyama-Fujita Y, Nakazato T, Iriyama N, et al. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Ann Med. 2022;54(1):1244–1254. doi: 10.1080/07853890.2022.2069280
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26(1):185–192. doi: 10.1093/annonc/mdu490
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Shan J, et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012;97(7):1029–1035. doi: 10.3324/haematol.2011.056721
   PubMed Web of Science ®Google Scholar
• Sakurai M, Mori T, Karigane D, et al. Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors. Int J Hematol. 2015;102(3):342–348. doi: 10.1007/s12185-015-1840-y
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Cortes J. Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature. Acta Haematol. 2014;132(3–4):298–306. doi: 10.1159/000363434
   PubMed Web of Science ®Google Scholar
• Peng N, Dou XL, Yu L, et al. [Clinical characteristics, treatment pattern, and outcomes in newly diagnosed patients with chronic myeloid leukemia in the chronic phase by age]. Zhonghua Xue Ye Xue Za Zhi. 2021;42(2):101–108. doi: 10.3760/cma.j.issn.0253-2727.2021.02.003
   PubMedGoogle Scholar
• Yanamandra U, Sahu KK, Karunakaran P, et al. Adolescent and young adult chronic myeloid leukemia in real-world settings: experience from a tertiary care institute in Northern India. J Adolesc Young Adult Oncol. 2019;8(1):94–97. doi: 10.1089/jayao.2018.0007
   PubMed Web of Science ®Google Scholar
• Yassin MA, Abdulla MA, Chandra P, et al. Chronic myeloid leukemia in adolescents and young adults: a single institute experience. Blood. 2019;134(Supplement_1):5915–5915. doi: 10.1182/blood-2019-126622
   Google Scholar
• Nakata K, Okawa S, Fuji S, et al. Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan. Cancer Sci. 2021;112(3):1150–1160. doi: 10.1111/cas.14808
   PubMed Web of Science ®Google Scholar
• Abdulla MA-J, Aldapt MB, Chandra P, et al. Chronic myeloid leukemia in adolescents and young adults: clinicopathological variables and outcomes. Blood. 2022;140(Supplement 1):3911–3912.
   Google Scholar
• Giles FJ, Rea D, Rosti G, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017;143(8):1585–1596. doi: 10.1007/s00432-017-2402-x
   PubMed Web of Science ®Google Scholar
• Ferrari A, Stark D, Peccatori FA, et al. Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open. 2021;6(2):100096. doi: 10.1016/j.esmoop.2021.100096
   PubMed Web of Science ®Google Scholar
• Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385–1415. doi: 10.6004/jnccn.2020.0047
   PubMed Web of Science ®Google Scholar
• Barr RD. Common cancers in adolescents. Cancer Treat Rev. 2007;33(7):597–602. doi: 10.1016/j.ctrv.2006.11.003
   PubMed Web of Science ®Google Scholar
• Coccia PF. Overview of adolescent and young adult oncology. J Oncol Pract. 2019;15(5):235–237. doi: 10.1200/JOP.19.00075
   PubMed Web of Science ®Google Scholar
• Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241–7. doi: 10.1007/s00277-015-2314-2
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol. 2009;22(3):295–302. doi: 10.1016/j.beha.2009.07.007
   PubMed Web of Science ®Google Scholar
• Miranda-Filho A, Piñeros M, Ferlay J, et al. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1):e14–e24. doi: 10.1016/S2352-3026(17)30232-6
   PubMed Web of Science ®Google Scholar
• Lin Q, Mao L, Shao L, et al. Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the global burden of disease study 2017. Front Oncol. 2020;10:580759. doi: 10.3389/fonc.2020.580759
   PubMed Web of Science ®Google Scholar
• Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a surveillance, epidemiology, and end results database analysis. Cancer. 2013;119(14):2620–2629. doi: 10.1002/cncr.28106
   PubMed Web of Science ®Google Scholar
• Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: an emerging field. J Clin Oncol. 2010;28(32):4781–4782. doi: 10.1200/JCO.2010.30.5128
   PubMed Web of Science ®Google Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–692. doi: 10.1182/blood-2010-12-319038
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56. doi: 10.1038/leu.2015.261
   PubMed Web of Science ®Google Scholar
• Brandt L. Comparative studies of bone marrow and extramedullary haemopoietic tissue in chronic myeloid leukemia. Ser Haematol. 1975;8(4):75–80.
   PubMedGoogle Scholar
• Baccarani M, Zaccaria A, Santucci AM, et al. A simultaneous study of bone marrow, spleen, and liver in chronic myeloid leukemia: evidence for differences in cell composition and karyotypes. Ser Haematol. 1975;8(4):81–112.
   PubMedGoogle Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–799. doi: 10.1182/blood.V63.4.789.789
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. Writing committee for the collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850–858. doi: 10.1093/jnci/90.11.850
   PubMedGoogle Scholar
• Peteet JR. Cancer and the meaning of work. Gen Hosp Psychiatry. 2000;22(3):200–205. doi: 10.1016/S0163-8343(00)00076-1
   PubMed Web of Science ®Google Scholar
• Dahl AA, Fosså SD, Lie HC, et al. Employment status and work ability in long-term young adult cancer survivors. J Adolesc Young Adult Oncol. 2019;8(3):304–311. doi: 10.1089/jayao.2018.0109
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Lauseker M, Hehlmann R, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99(9):1441–1447. doi: 10.3324/haematol.2013.096537
   PubMed Web of Science ®Google Scholar
• Owojuyigbe TO, Durosinmi MA, Bolarinwa RAA, et al. Distribution of BCR–ABL1 transcript variants in Nigerians with chronic myeloid leukemia. Indian J Hematol Blood Transfus. 2020;36(4):646–651. doi: 10.1007/s12288-020-01264-1
   PubMed Web of Science ®Google Scholar
• Goranova-Marinova V, Linev A, Ivanov HJ, et al. Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation. Folia Med (Plovdiv). 2021;63(5):670–675. doi: 10.3897/folmed.63.e63366
   PubMedGoogle Scholar
• Vacarean-Trandafir IC, Ivanov IC, Dragos LM, et al. ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance. Mol Biol Rep. 2019;46(4):3747–3754. doi: 10.1007/s11033-019-04816-5
   PubMed Web of Science ®Google Scholar
• Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019;3(24):4280–4290. doi: 10.1182/bloodadvances.2019000865
   PubMed Web of Science ®Google Scholar
• Ono T. Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers (Basel). 2021;13(20):5116. doi: 10.3390/cancers13205116
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Carmosino I, et al. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse? Eur J Haematol. 2018;101(5):578–584. doi: 10.1111/ejh.13110
   Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340. doi: 10.1200/JCO.2015.64.8899
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica. 2018;103(8):1298–1307. doi: 10.3324/haematol.2017.171249
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054. doi: 10.1038/leu.2016.5
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–453. doi: 10.1038/s41375-020-01111-2
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Latagliata R, Breccia M, et al. Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML. Cancer. 2023. doi: 10.1002/cncr.34923.
   Google Scholar
• NCT04070443. NCT04070443, in A multicentre, open-label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult patients with chronic myelogenous leukemia in chronic phase (CML-CP) ≤ 65 years.
   Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014;93(1):71–80. doi: 10.1007/s00277-013-1937-4
   PubMed Web of Science ®Google Scholar
• Shaya J, Pettit K, Kandarpa M, et al. Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leukemia. 2022;22(1):17–23. doi: 10.1016/j.clml.2021.07.001
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Eskazan AE. Tyrosine kinase inhibitor sequencing in patients with chronic myeloid leukemia. Oncol Ther. 2019;7(2):95–100. doi: 10.1007/s40487-019-00098-w
   PubMed Web of Science ®Google Scholar
• Anderson KR, Chambers CR, Lam N, et al. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract. 2015;21(1):19–25. doi: 10.1177/1078155213520261
   PubMed Web of Science ®Google Scholar
• Geissler J, Sharf G, Bombaci F, et al. Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143(7):1167–1176. doi: 10.1007/s00432-017-2372-z
   PubMed Web of Science ®Google Scholar
• Santoleri F, Lasala R, Ranucci E, et al. Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematol. 2016;136(1):45–51. doi: 10.1159/000444626
   PubMed Web of Science ®Google Scholar
• Jiang Q, Liu Z-C, Zhang S-X, et al. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142(7):1539–1547. doi: 10.1007/s00432-016-2159-7
   PubMed Web of Science ®Google Scholar
• Boons C, Hartog YM, Janssen JJWM, et al. Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): enabling dose reduction and relief of treatment burden. Eur J Haematol. 2020;105(2):148–155. doi: 10.1111/ejh.13418
   PubMed Web of Science ®Google Scholar
• Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012;28(2):213–219. doi: 10.1185/03007995.2011.649849
   PubMed Web of Science ®Google Scholar
• Latremouille-Viau D, Guerin A, Nitulescu R, et al. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States. J Med Econ. 2017;20(1):63–71. doi: 10.1080/13696998.2016.1225578
   PubMed Web of Science ®Google Scholar
• Phuar HL, Begley CE, Chan W, et al. Tyrosine kinase inhibitors and the relationship with adherence, costs, and health care utilization in commercially insured patients with newly diagnosed chronic myeloid leukemia: a retrospective claims-based study. Am J Clin Oncol. 2020;43(7):517–525. doi: 10.1097/COC.0000000000000700
   PubMed Web of Science ®Google Scholar
• Skrabal Ross X, Gunn KM, Suppiah V, et al. A review of factors influencing non-adherence to oral antineoplastic drugs. Support Care Cancer. 2020;28(9):4043–4050. doi: 10.1007/s00520-020-05469-y
   PubMed Web of Science ®Google Scholar
• Bouwman L, Eeltink CM, Visser O, et al. Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation. BMC Cancer. 2017;17(1):739. doi: 10.1186/s12885-017-3735-1
   PubMed Web of Science ®Google Scholar
• Algarroba GN, Sanfilippo JS, Valli-Pulaski H. Female fertility preservation in the pediatric and adolescent cancer patient population. Best Pract Res Clin Obstet Gynaecol. 2018;48:147–157. doi: 10.1016/j.bpobgyn.2017.10.009
   PubMed Web of Science ®Google Scholar
• Sugishita Y, Suzuki N. [Practice of fertility preservation for cancer patients in the AYA generation]. Gan To Kagaku Ryoho. 2017;44(1):12–18.
   PubMedGoogle Scholar
• Michalczyk K, Cymbaluk-Płoska A. Fertility preservation and long-term monitoring of gonadotoxicity in girls, adolescents and young adults undergoing cancer treatment. Cancers (Basel). 2021;13(2):202. doi: 10.3390/cancers13020202
   PubMed Web of Science ®Google Scholar
• Alizadeh H, Jaafar H, Rajnics P, et al. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res. 2015;39(1):47–51. doi: 10.1016/j.leukres.2014.10.002
   PubMed Web of Science ®Google Scholar
• P P, Samal R, Ghose S. Chronic myeloid leukaemia in pregnancy: call for guidelines. J Obstet Gynaecol. 2019;39(4):582–583. doi: 10.1080/01443615.2018.1534815
   PubMedGoogle Scholar
• Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505–5508. doi: 10.1182/blood-2007-10-114900
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Dasgupta S, Kanti Ray U, et al. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci. 2015;184(1):183–188. doi: 10.1007/s11845-014-1084-5
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ali Z, Khan AUN, et al. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2014;55(9):2109–2113. doi: 10.3109/10428194.2013.866662
   PubMed Web of Science ®Google Scholar
• Santos FM, Ghelfond G, Seguro FS, et al. Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia. Am J Hematol. 2022;97(2):E72–E74. doi: 10.1002/ajh.26424
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Alcazer V, Huguet F, et al. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. Leuk Res. 2016;48:80–83. doi: 10.1016/j.leukres.2016.07.008
   PubMed Web of Science ®Google Scholar
• Carlier P, Bernard N, Lagarce L, et al. Erratum to: pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet. 2017;295(4):1059. doi: 10.1007/s00404-017-4321-0
   PubMed Web of Science ®Google Scholar
• Chelysheva E, Aleshin S, Polushkina E, et al. Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review. Mediterr J Hematol Infect Dis. 2018;10(1):e2018027. doi: 10.4084/mjhid.2018.027
   PubMedGoogle Scholar
• Dou X, Qin Y, Huang X, et al. Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Oncology. 2019;24(11):e1141–e1147. doi: 10.1634/theoncologist.2019-0109
   Google Scholar
• Ćojbašić I, Mačukanović-Golubović L, Vučić M, et al. Analyses of treatment outcome according to age in patients with chronic myeloid leukemia receiving front-line imatinib therapy. Clin Lymphoma Myeloma Leukemia. 2017;17(10):696–702. doi: 10.1016/j.clml.2017.06.025
   PubMed Web of Science ®Google Scholar
• Tarafdar A, Hopcroft LE, Gallipoli P, et al. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood. 2017;129(2):199–208. doi: 10.1182/blood-2016-09-742049
   PubMed Web of Science ®Google Scholar
• Hassan IB, Benedict S, Kristensen J. Cytokine syntheses by T-Cell subsets from chronic myeloid leukemia patients: relationship between pre-treatment levels and response to imatinib therapy. J Hematol. 2018;7(3):96–106. doi: 10.14740/jh410w
   PubMedGoogle Scholar
• Ureshino H, Shindo T, Kimura S. Role of cancer immunology in chronic myelogenous leukemia. Leuk Res. 2020;88:106273. doi: 10.1016/j.leukres.2019.106273
   PubMed Web of Science ®Google Scholar
• Sender L, Zabokrtsky KB. Adolescent and young adult patients with cancer: a milieu of unique features. Nat Rev Clin Oncol. 2015;12(8):465–480. doi: 10.1038/nrclinonc.2015.92
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404. doi: 10.1182/blood-2016-09-739086
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237. doi: 10.1200/JCO.2017.74.7162
   PubMed Web of Science ®Google Scholar
• Sung-Hyun K, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014;99(7):1191–1196. doi: 10.3324/haematol.2013.096776
   PubMed Web of Science ®Google Scholar
• Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–2041. doi: 10.1182/blood.2020009984
   PubMed Web of Science ®Google Scholar
• Kılıçaslan NA, Börekçi Ş, Özdemir GN, et al. Dasatinib-related pleural effusion and lymphocytosis rates are different between adult and pediatric patients with Philadelphia chromosome-positive leukemias: are age and comorbidities only to blame? Expert Rev Respir Med. 2022;16(8):849–852. doi: 10.1080/17476348.2022.2122445
   PubMed Web of Science ®Google Scholar
• Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42–50. doi: 10.1001/jamaoncol.2020.5774
   PubMed Web of Science ®Google Scholar
• Shima H, Kada A, Tanizawa A, et al. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia. Pediatr Blood Cancer. 2022;69(8):e29699. doi: 10.1002/pbc.29699
   PubMed Web of Science ®Google Scholar
• Zhao HF, Yang YF, Liu BC, et al. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(8):636–643. doi: 10.3760/cma.j.issn.0253-2727.2022.08.004
   PubMedGoogle Scholar